Real-world study of direct oral anticoagulant dosing patterns in patients with atrial fibrillation
Background: Direct oral anticoagulants (DOACs) are preferred for stroke prevention in atrial fibrillation (AF). However, off-label doses have been associated with increased risk of adverse events. Objective: The objective of this study was to compare the frequency and outcomes of labeled versus off-label DOAC dosing in patients with AF. Methods: This retrospective cohort study included adults diagnosed with nonvalvular AF (NVAF), discharged from University of Utah Health on DOAC therapy between 7/1/2017 and 9/30/2017. The primary outcome was off-label DOAC dosing frequency, defined as dosing inconsistent with manufacturer labeling. Secondary outcomes included variables associated with off-label dosing and a composite of adverse events (major bleeding, thromboembolism, and all-cause mortality) in the 90 days following the index hospital discharge. Results: Of 249 included patients, 16.1% were discharged with off-label dosing. Factors associated with off-label dosing included advanced age, lower body mass index, decreased renal function, use of rivaroxaban, and hepatic impairment. The majority of off-label patients (70%) received lower-than-recommended DOAC dosing. Prescriber rationale for off-label prescribing was documented in 25% of patients and included anti-Xa guided dosing, high risk for bleeding or thromboembolism, and prior history of on-therapy adverse events. The rate of adverse events between labeled and off-label DOAC doses was not statistically different (10.0% vs. 6.7%, p=0.299), although this is likely due to small sample size. Conclusions: Off-label DOAC prescribing for stroke prevention in NVAF at University of Utah Health was consistent or lower than previously published studies. Off-label dosing most often involved under-dosing of rivaroxaban. Future research should investigate the role of provider rationale and insight in optimizing DOAC therapy outcomes.
Main Authors: | Gustafson,Whitney L, Saunders,John, Vazquez,Sara R, Jones,Aubrey E, Witt,Daniel M |
---|---|
Format: | Digital revista |
Language: | English |
Published: |
Centro de Investigaciones y Publicaciones Farmacéuticas
2019
|
Online Access: | http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1885-642X2019000400017 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Importance of dose selection in novel oral anticoagulants for atrial fibrillation
by: Grip,Laura T., et al.
Published: (2012) -
Prevalence of oral anticoagulation in atrial fibrillation
by: Bartholomay,Eduardo, et al.
Published: (2014) -
Occult gastrointestinal disease unmasked by direct oral anticoagulants used for the prevention of atrial fibrillation
by: Colín,Luis, et al.
Published: (2018) -
Challenges for Anticoagulation in Atrial Fibrillation
by: Bronchtein,Ana Inês da Costa
Published: (2020) -
Oral anticoagulants and atrial fibrillation: A South African perspective
by: Laäs,D J, et al.
Published: (2018)